Quince Therapeutics Announces First Patient Dosed in Phase 3 Clinical Trial of EryDex for the Treatment of Ataxia-Telangiectasia

View Full Size 

Download

• Full Size JPEG, 1121x442, 113.1 KB
• Small JPEG, 480x189, 61.9 KB
• Preview JPEG, 144x57, 28.5 KB
• Thumbnail JPEG, 120x47, 26.0 KB